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Abstract: Atypical antipsychotics have become a widely utilized component of the bipolar 
disorder treatment armamentarium, with approximately 45% of bipolar patients prescribed 
atypicals. Over the last decade all atypical drugs except for clozapine have received a Food 
and Drug Administration (FDA) bipolar indication. In October 2008, the FDA approved 
quetiapine XR monotherapy for the treatment of acute depressive episodes of bipolar disorder 
and acute manic or mixed episodes in bipolar I disorder based on two placebo-control 
trials. Quetiapine was also approved as adjunct therapy with lithium and divalproex for the 
treatment of acute manic or mixed episodes as well as maintenance of bipolar I disorder. 
In contrast to immediate release quetiapine which may require a twice-daily regimen, the XR 
formulation is intended for once-daily administration. This drug profile of quetiapine XR will 
address chemistry, pharmacodynamics, pharmacokinetics, metabolism, safety and tolerability 
and clinical trials in bipolar disorder.
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Introduction
Bipolar disorder is a life-long clinical illness characterized by the presence of cycling 
episodes of mania or hypomania and mostly episodes of depression. Men and women 
are equally affected across all ethnicities with an overall lifetime prevalence of about 
2%–3%.1
Treatment of bipolar disorder must also address: 1) acute intervention for manic 
or depressive episodes, 2) maintaining long term remission and 3) prevention of 
recurrence. However, a major challenge has been that different medications may 
have limited therapeutic benefit for the disorder’s polarity of symptoms or only have 
specific efficacy in certain phases of the illness. Moreover, medications may treat acute 
symptoms but not necessarily offer long-term maintenance.
Lithium has been used since the 1960s, often as first-line treatment for bipolar 
disorder.2 Major drawbacks to lithium include a narrow therapeutic window, a fairly 
long onset of action (1 to 3 weeks), and some may develop a tolerance over time.3,4
In the mid 1990s, the US Food and Drug Administration (FDA) approved the 
anticonvulsant valproate for the treatment of bipolar disorder.5,6 Other FDA-approved 
anticonvulsants for bipolar disorder include lamotrigine for bipolar maintenance and 
carbamazepine for acute mania.7,8 Typical antipsychotic drugs such as haloperidol 
and chlorpromazine are also used in the treatment of patients with bipolar disorder 
although side effects such as extrapyramidal symptoms (EPS) and tardive dyskinesia 
may limit their use.Neuropsychiatric Disease and Treatment 2010:6 30
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Atypical antipsychotics have become a widely used 
for the treatment of bipolar disorder. Using data from the 
Veterans Affairs National Psychosis Registry, Sajatovic 
and colleagues reported that 45% of subjects with bipolar 
disorder were on antipsychotics (n = 73,964) as monotherapy 
or combination therpay.9 The great majority of individuals 
prescribed antipsychotic agents received atypical compounds 
(n = 25,559, 94.7%). The progressive increase in utilization 
of atypical antipsychotics in bipolar disorder is well docu-
mented. Depp and colleagues reviewed data of Medicaid 
beneficiaries with bipolar disorder receiving services in the 
San Diego County public mental health system.10 A total of 
1473 clients were identified and trends of medications pre-
scription were reviewed from 2001 to 2004. The percentage 
of subjects prescribed mood stabilizers or antipsychotics 
increased significantly, from 71% in 2001 to 77% in 2004 
(P  0.001). Interestingly, the percentage of subjects on mood 
stabilizers alone decreased from 25% to 20% (P = 0.001), 
while the use of antipsychotics alone increased from 32% 
to 36% (P = 0.008).
Over the last decade all atypical drugs except for 
clozapine have received Food and Drug Administration 
(FDA) bipolar indication. Side effect concerns with the 
atypical agents primarily involve abnormalities in metabolic 
functioning including medication-related diabetes as well as 
weight gain.
Both treatment efficacy and treatment-related adverse 
effects of different medication classes vary substantially 
between individual patients. For example, it is not possible 
to predict which individuals will go on to develop EPS from 
antipsychotic drugs, although risk is higher in general with 
high-potency typical compounds, high-doses and long-term 
use. Similarly, current technologies do not permit prediction 
of which individuals will experience the rare but serious side 
effect of Stevens–Johnson Syndrome that can occur with 
lamotrigine therapy, although risk is elevated in situations 
where dosing titration is rapid. Additionally across all bipolar 
medication pharmacotherapies rates of partial and full treat-
ment nonadherence are in the order 50%, indicating a need 
for treatments that are better accepted by patients.10
Newer formulations of currently approved bipolar medi-
cation treatments, such as extended-release formulations, 
orally dissolving tablets and injectable medications, may 
offer an opportunity to minimize side effects or improve 
patient acceptance or adherence. An extended-release (XR) 
formulation of quetiapine has recently been approved in 
the treatment of bipolar disorder and is intended to be 
administered as a once-daily dosing. However, it is not clear 
if a reduced dosing frequency will translate into greater 
acceptability or long-term adherence by patients with bipolar 
illness. This manuscript will examine the drug profile of 
quetiapine XR by addressing chemistry, pharmacodynamics, 
pharmacokinetics, metabolism, safety and tolerability, and 
clinical trials in bipolar disorder.
Introduction to the compound
Quetiapine XR is an atypical antipsychotic, belonging to what 
is generally referred to as second generation antipsychotics. 
Its active metabolite is N-desalkylquetiapine (norquetiapine). 
Quetiapine XR was approved in the United States in 2007 
for the acute treatment as well for maintenance therapy of 
schizophrenia in adult patients. In October 2008, it gained 
FDA approval as monotherapy for treatment for bipolar dis-
order-acute depressive episodes, and bipolar I disorder-acute 
manic or mixed episodes. It also has FDA approval as adjunct 
therapy with lithium or divalproex for bipolar I disorder acute 
manic or mixed episode and maintenance.11 Quetiapine XR 
is available in 50 mg, 150 mg, 200 mg, 300 mg and 400 mg 
prolonged release tablets.
Chemistry of quetiapine XR
Quetiapine extended release is a dibenzothiazinepine anti-
psychotic. The chemical designation is 2-[2-4-dibenzo[b,f] 
[1,4]thiazepin-11-yl-piperzinyl)ethoxy]-ethanol fumarate 
(2:1). Its molecular formula is C42H50N6O4S2.C4h4O4 and it 
has a molecular weight of 883.11.11
Pharmacodynamics and mechanism 
of action
Quetiapine has an affinity for multiple receptors most 
notably dopamine and serotonin. The reported dissocia-
tion constant values (Ki) are 428 and 626 nmol/L for D1 
and D2 receptors; and 1040 and 38 nmol/L for 5-HT1A and 
5-HT2A receptors.11 Quetiapine displays affinity for α1b and 
α2b-adrenoceptors (Ki 14.6 and 617 nmol/L), histamine H1 
receptors (Ki 4.41 nmol/L) but lacks significant affinity for 
muscarinic cholinergic (M1) (Ki 1086 nmol/L) or benzodi-
azepines receptors (Ki  10000 nmol/L).12
Norquetiapine differs from quetiapine in having a higher 
affinity for serotonin M1 receptors (Ki 38.3 nmol/L), 5HT2A 
(Ki 2.9 nmol/L), 5HT1A (Ki 45 nmol/L) and norepinephrine 
neurotransporter (Ki 12 nmol/l).13
The mood-stabilizing effects of quetiapine and que-
tiapine XR in bipolar disorder are believed to be mediated 
mostly through combined effect D2 and 5-HT2A receptor 
antagonism. The mechanism effect on bipolar depression is Neuropsychiatric Disease and Treatment 2010:6 31
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less understood. The norepinephrine reuptake inhibition by 
norquetiapine has been suggested as a possible mechanism. 
Increased endogenous that have been related to depres-
sion. Quetiapine antihistaminic effect has been reported 
to indirectly down regulate endogenous cytokines such 
as interleukine 1b and interleukine-6 and thus can partly 
explain quetiapine XR effect on bipolar depression and 
mixed phases.14,15
Pharmacokinetics and metabolism
Quetiapine XR is well absorbed. Plasma concentration of 
quetiapine and norquetiapine are proportionate to the total 
daily dose. Peak plasma concentration of quetiapine XR is 
often reached in 6 hours, with a mean terminal half-life of 
7 hours. At therapeutic levels, quetiapine has a volume of 
distribution of 10 L/kg with 83% plasma protein binding. 
Absorption of quetiapine XR is highly affected by food 
intake. It is reported that a meal with high fat content can 
increase quetiapine XR Cmax from 44% to 52% and AUC from 
20% to 22% for the 50 mg and 300 mg tablets, respectively. 
Steady state concentrations are expected within 2 days of 
dosing.11
Quetiapine XR is metabolized by the liver. The primary 
pathways are via sulfoxidation and oxidation. In vitro studies 
report involvement of the cytochrome P450 3A4 isoenzyme. 
Using radiolabeled 14C-quetiapine, studies showed that 73% 
of the dose is recovered in urine and 20% from stools. Less 
than 1% of quetiapine XR is excreted unchanged.11
The quetiapine XR manufacturers’ prescribing informa-
tion reflects no need for dose adjustment in patients with 
decreased renal functions. A report of 8 subjects with severe 
renal insufficiency showed a 25% decrease in medication 
clearance compared to controls.16 However, the quetiapine 
XR dose continued to be within normal concentration range. 
However, the Electronic Medicine Compendium calls for 
using quetiapine XR with caution in patient with renal 
insufficiency.17
Dosage adjustments are recommended for patients 
with hepatic insufficiency.11 Liver functions deficiencies 
can significantly increase AUC and Cmax to up to 3 times 
compared to those seen in healthy subjects. Accordingly, 
medication dosage adjustment is highly recommended in 
this subpopulation.
Figueroa and colleagues18 compared pharmacokinetic 
profiles of quetiapine XR and quetiapine immediate release 
(IR) in patients with schizophrenia, and schizoaffective and 
bipolar disorder. In this open-label, randomized, crossover 
trial, all 28 subjects received quetiapine IR 150 mg mg 
twice a day and quetiapine XR 300 mg daily over 4-day 
treatment intervals. Over a 24-hour dosing interval, Cmax of 
quetiapine XR was 13% less than quetiapine IR (495.3 vs 
568.1 ng/ml, 90% confidence interval [CI] 0.77 to 0.99). 
Camx was achieved in 5 hours with quetiapine XR compared 
to 2 hours with quetiapine IR. Morning trough quetiapine 
concentrations (Cmin) showed no difference between the 
XR and IR formulations with 95.3 ng/mL and 96.5 ng/mL, 
respectively, (90% CI 0.77 to 1.31).
With similar AUC and oral clearance for both formula-
tions of quetiapine, drug–drug interaction data of quetiapine 
XR can be extrapolated from the quetiapine IR studies.18 
Quetiapine IR has a limited inhibitory effect on cytochrome 
P450 enzymes 1A2, 2DC, 2C19, 2D6 and 3A4 substrates.11 
Its plasma concentration and clearance is affected by cyto-
chrome 3A4 inhibitors and inducers. For example, keto-
conazole slows quetiapine metabolism and thus increase its 
plasma concentration while phenytoin, carbamazepine and 
thioridazine lower it.17
Clinical efficacy
As monotherapy, the FDA-approved quetiapine XR for the 
treatment of acute depressive episodes of bipolar disorder and 
acute manic or mixed episodes in bipolar I disorder based on 
two placebo-control trials (see Table 1). The FDA has also 
approved it as adjunct therapy with lithium and divalproex 
for the treatment of acute manic or mixed episodes as well as 
maintenance of bipolar I disorder, though this latter approval 
appears to be based on extrapolated data from quetiapine IR 
studies.11
Monotherapy treatment for acute mania/
mixed episodes
The FDA approval of quetiapine XR for acute mania/mixed 
episode was based on a study by Cutler and colleagues.19 
This randomized, multicenter, double-blind, parallel-group, 
placebo-controlled study included a total of 308 subjects with 
bipolar I with or without history of rapid cycling who were 
in acute manic or mixed episodes. Subjects recruited were 
18 to 65 years of age with a Young Mania Rating Scale (YMRS) 
of  20, and Clinical Global Impression-Bipolar-Severity 
of Illness (CGI-BP-S) overall score of  4. All subjects 
were hospitalized for at least 4 days at the beginning of the 
study. One hundred and forty-nine subjects were random-
ized to receive quetiapine XR initiated at 300 mg at the first 
day and increased to 600 mg the following day. The target 
flexible daily dose ranged from 400 to 600 mg. The primary 
outcome measure was change of YMRS total score after Neuropsychiatric Disease and Treatment 2010:6 32
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3 weeks of randomization. Secondary outcomes included 
YMRS remission rate (YMRS  12), response rate (50% 
reduction in YMRS score) as well as changes in CGI-BP-S 
and CGI-BP-change (CGI-BP-C).
At the end of the study, subjects on quetiapine XR 
showed a statistically significant decline in total YMRS 
scores compared to placebo (–14.34 vs –10.52, P  0.001). 
Among subjects on quetiapine XR, 55.0% showed response 
and 41.6% remission compared to only 33.3% and 27.7% 
on placebo (P  0.001 and P = 0.006).
Monotherapy treatment for acute 
depressive episodes
Suppes and colleagues have published data supporting the 
indication of quetiapine XR for the acute treatment of depres-
sion of bipolar I or II.20
Two hundred and eighty subjects were recruited in this 
study. They were aged 18 to 65 years of age with a Hamilton 
Depression Rating Scale-17 (HAMD-17) of at least 20 and 
YMRS of less than 12. Subjects were randomized to either 
placebo or quetiapine XR with the later being progressively 
tapered to a total of 300 mg daily by day 4 of the study.
Changes in Montgomery-Åsberg Depression Rating 
Scale (MADRS) scores from baseline to end of the 
study was the primary outcome measure, while response 
(MADRS  reduction in MADRS scores), remission 
(MADRS  12), CGI-BP-S and CGI-BP-C were considered 
as secondary outcomes. By the end of the study, subjects 
on quetiapine XR showed on average a 17.4 point drop on 
total MADRS scores compared to 11.9 for those receiving 
placebo (P  0.001). The separation between the two 
arms was evident as early as week one of randomization. 
Response was achieved by 65% of patients on active 
medication compared to 43.1% on placebo (P  0.001). 
Similarly, more subjects on quetiapine XR achieved 
remission than placebo (54.1% vs 39.4%; P = 0.018). 
A mean decrease in CGI- BP-S of 1.82 was reported among 
the quetiapine XR arm compared to 1.25 in the placebo arm 
(P  0.001). Finally, 63.2% of subjects receiving quetiapine 
XR reported “much improved” or “very much improved” 
by the end of the study on CGI-BP-C, compared to 39.4% 
receiving placebo.
Safety and tolerability
Common adverse events
Available data from the two placebo-controlled trials 
provide information on adverse events that may be expected 
when quetiapine XR is prescribed to patients with bipolar 
disorder.17,18 These side effects were observed at a mean daily 
dose of quetiapine XR of 604 mg (range 400 to 800 mg) over 
3-week period for the mania study, and a fixed daily dose of 
300 mg over 8 weeks for the acute depression study.
Discontinuation rates were comparable to placebo though 
nearly a third of subjects receiving active medication withdrew 
from both studies. In the acute mania study, 44 participants 
(n = 151) receiving quetiapine XR did not complete the study 
protocol: 12 lost to follow up, 13 voluntary termination, 
6 lack of response, 3 worsening of condition and only 4 for 
adverse events.19 In comparison, 45 subjects in the placebo 
arm (n = 161) had an early termination with 15 report-
ing lack of response, 12 adverse events, and 12 voluntary 
discontinuation.
Table 1 Summary of quetiapine Xr acute mania and acute bipolar depression studies
Quetiapine XR for acute mania Quetiapine XR for acute bipolar depression
Author Cutler A, et al19 Suppes T et al20
Design randomized, parallel-group, double-blind, 
placebo-controlled
randomized, parallel group double-blind, 
placebo controlled
Sample size Quetiapine Xr = 149, placebo arm = 159 Quetiapine Xr = 140, placebo = 140
Duration 3 weeks 8 weeks
Mean daily dosage (range) 604 mg (400–800 mg) 300 mg
Primary outcomes Subjects on quetiapine Xr showed a statistically 
significant decline in total YMRS scores compared 
to placebo (–14.34 vs –10.52, P  0.001)
Subjects on quetiapine Xr showed a statistically 
significant decline in total MADRS scores 
compared to placebo (–17.4 vs –11.9, P  0.001).
reported side effects Sedation (34.4%), dry mouth (33.8%), somnolence 
(16.6%), headaches (11.9%), constipation (9.9%), 
dizziness (9.9%), dyspepsia (6.6%), fatigue 
(6.6%) and weight gain (6.6%)
Dry month (37.2%), somnolence (29.2%), sedation 
(23.4%), dizziness (13.1%), increased appetite (12%), 
headache (9.5%), constipation (8.0%), nausea (7.3%), 
weight gain (7.3%), dyspepsia (6.6%), fatigue (5.8%)
Abbreviations: YMRS, Young Mania Rating Scale; CGI-BP-S, Clinical Global Impression-Bipolar-Severity of Illness; CGI-BP-C, Clinical Global Impression-Bipolar-change; 
MADrS, Montgomery-Åsberg Depression rating Scale;  Ae, adverse events; ePS, extrapyramidal symptoms.Neuropsychiatric Disease and Treatment 2010:6 33
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In the acute bipolar depression study, Suppes et al 
reported an early termination of 37% in the active arm 
(n = 140) and 30% in the placebo arm (n = 140).20 Most 
common reasons for discontinuation in the quetiapine XR 
cohort were adverse events, lost to follow up and voluntary 
discontinuation in 17, 12 and 12 cases respectively. Lack of 
therapeutic response and voluntary discontinuation were the 
most common reasons for early termination in the placebo 
cohort with 10 cases each, followed by 8 lost to follow up 
and adverse events cited as a reason in only 2 cases.
During the 8-week acute depression study, the most 
commonly reported side effects were dry mouth (37.2%), 
sedation (23.4%), somnolence (29.2%), increase appe-
tite (12.4%), headache (9.5%) constipation (8%), nausea 
(7.3%), weight gain (7.3%), dyspepsia (6.6%) and fatigue 
(5.8%).20 Similarly, sedation (34.4%), dry mouth (33.8%), 
somnolence (16.5%) and headache (11.9%) were the most 
commonly reported side effects in the 3-week period of the 
acute mania study.19
There was no reported incidence of mania or hypomania 
reported in the acute depression study. However, two adverse 
events related to suicidal ideation/behavior were reported 
in the placebo arm and in one in the quetiapine arm.20 No 
incidence of new depression was reported in the acute mania 
study.19
extrapyramidal symptoms
The use of quetiapine XR in bipolar disorder has been 
associated with extrapyramidal side effects. In the 3-week 
acute mania study, EPS, ie, akathesia, dystonia, hypertonia, 
tremors and extrapyramidal disorder, were reported in 4.4% 
of subjects compared to 0.7% in the placebo arm.19
Body weight changes
In a 3-week study of quetiapine XR in the treatment of 
bipolar mania, weight gain was noted to be relatively 
modest.17 Mean body weight changes were 1.3 kg for 
the quetiapine XR-treated patients and 0.1 kg for the 
placebo-treated patients. Body weight increase of 7% 
was reported in 5.1% of subjects receiving quetiapine XR 
compared to none in the placebo arm. In the 8-week acute 
bipolar depression study, the mean average weight gain 
for quetiapine was 1.3 kg compared to a 0.2 kg weight 
loss in the placebo arm. Body weight increase of 7% 
was reported in 8.2% of subjects receiving quetiapine XR 
compared to 0.8% in those receiving placebo. Long-term 
effect of quetiapine XR on weight gain in bipolar subjects 
has not been reported. Modest or moderate long term weight 
gain with quetiapine however has been reported with a 
mean average of 3.3 kg over a 12-week period (mean dose 
of 618 mg and range of 400 to 800 mg daily).21
Serum prolactin level
Prolactin level changes were reported in the acute mania 
study.19 The mean prolactin level in the quetiapine XR arm 
(n = 126) at baseline was 9.27 ng/mL compared to 8.28 ng/mL 
in the placebo arm (n = 145). At the end of the 3-week study, 
there was a mild increase in the quetiapine XR arm mean 
level to 10.02 ng/ml and relatively no change in the placebo 
arm (8.22 ng/mL). No prolactin data were reported in the 
acute depression study.
Metabolic risk factors
In the acute mania study, Cutler and colleagues reported that 
10.1% of subjects (n = 160) the placebo arms had a signifi-
cant shift in blood pressure (130 systolic or 85 diastolic) 
compared to only 4.7% in the quetiapine XR arm (n = 151).19 
However, the opposite was seen in fasting blood sugar where 
4.1% of quetiapine XR treated subjects had a significantly 
high shift of fasting or random blood sugar (5.55 mmol/L) 
compared to only 1.6% in the placebo-treated cohort. Tri-
glyceride changes were comparable between the two cohorts 
of the studies with less than 3% of subjects showing a shift 
in triglyceride levels to  1.7 mmol/L. Only one subject in 
each arm had a significant decrease in high-density lipo-
protein cholesterol to below normal levels. Similarly one 
subject in each group had a significant increase in waist 
circumference. The combined effect of these factors reflects 
that total percentage of patients with 3 or more factors for 
metabolic syndrome at the end of 3-week study was 12.5 in 
quetiapine XR arm and 12.6% in the placebo arm.19
By the end of the 8-week acute bipolar depression study, 
the results showed fairly similar side effects profiles, with 
5.8% of quetiapine-treated subjects (n = 137) showing a 
significant increase in fasting glucose levels compared to 
2.4% in the placebo-treated subjects (n = 141).20 Similarly, 
5.18% of the quetiapine XR cohort had significant increase in 
cholesterol level compared to only 2.8% in the placebo arm. 
Triglyceride shifts to clinically significant ranges were seen 
in 8.3% and 7.5% of quetiapine XR and placebo subjects, 
respectively.20
Conclusion
Atypical antipsychotics have been increasingly used for the 
treatment of bipolar disorder. Recently presented data from 
two clinical trials in bipolar disorder patients demonstrated Neuropsychiatric Disease and Treatment 2010:6 34
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efficacy in the treatment of acute bipolar depression and 
acute mania. Adverse events of particular concern with 
quetiapine XR, similar to quetiapine IR, include somno-
lence, sedation, dizziness, EPS, weight gain and metabolic 
abnormalities.
Expert opinion
Efficacy between quetiapine XR and the immediate 
formatulation appear similar although there is no data on 
comparative efficacy of quetiapine XR versus quetiapine 
IR in patients with bipolar disorder. Möller et al reported 
comparable efficacy and adverse events profile between 
quetiapine IR twice per day and quetiapine XR once daily 
among subjects with schizophrenia.22 Quetiapine XR offers 
the benefit of once-daily dosage over quetiapine IR which is 
often dosed twice daily. Adverse effects with quetiapine XR 
do not generally appear vastly different from those reported 
in bipolar clinical trials with quetiapine IR.21,23–26
Though approved as an add-on to lithium or divalproex, 
there is no published study of quetiapine XR in bipolar 
patients as an add-on to either medication. However, com-
bination therapy seems to be the rule rather than exception 
in treatment of bipolar disorder. In retrospective study 
of 2442 subjects enrolled in the Systematic Treatment 
Enhancement Program for Bipolar Disorder (STEP-BD) 
and who achieved full recovery for at least 8 consecutive 
weeks, the reported average number of prescribed psychotic 
medications was 2.05 (SD = 1.11).27 The use of an atypical 
antipsychotic with a mood stabilizer is a common practice 
in inpatient as well as outpatient settings.
A comprehensive approach for the treatment of bipolar 
disorder calls for an early and accurate diagnosis, building a 
therapeutic alliance, psychotherapeutic intervention, proper 
monitoring and follow-up, and the proper selection of medi-
cation combinations. The last-named factor is influenced by 
demographic factors as well as past psychiatric and medical 
history and treatment of the patient and family members.
An important consideration, which has not been evalu-
ated for quetiapine XR, is its effects on treatment adherence 
in comparison to bipolar treatments that are dosed more 
than once daily. Dosage simplification measures, including 
reduction in daily dosing frequency, are known to improve 
treatment adherence in most psychiatric and medical popula-
tions. For example, a review by Claxton and colleagues across 
multiple disease states demonstrated an apparent relation-
ship between adherence rates and dosing frequency with 
adherence of 79% for medications that required once-daily 
administration, 69% for twice-daily dosing and 65% for 
three-times-daily dosing.28 Studies are needed to address the 
clinically relevant question of whether quetiapine XR actually 
improves treatment adherence compared to quetiapine IR 
when it is dosed more than once daily.
Five-year view
The use of atypical antipsychotics in the treatment of 
bipolar disorder is a current standard of care.29 The role 
of atypical antipsychotics in the treatment of acute mania, 
acute bipolar depression and maintenance treatment is well 
established.
Quetiapine XR offers a longer-acting formulation with 
a potential role in maximizing adherence, but this needs a 
more focused assessment. Treatment nonadherence among 
subjects with bipolar disorder is estimated be around 40% 
and is associated with substantial humanitarian and financial 
burdens.30–32 While a once-daily treatment is likely to improve 
adherence for individuals who forget to take medication 
twice daily, formulations that require an even less frequent 
administration and perhaps with routes other than oral 
(ie, long-acting injectable compounds) such as once-weekly 
or once every 1 to 3 months should be a subject of future 
research focus.
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